Indivior (NASDAQ:INDV) Stock Price Down 4.2% – Here’s What Happened

Indivior PLC (NASDAQ:INDV) shares were down 4.2% during trading on Wednesday . The stock traded as low as $9.33 and last traded at $9.41. Approximately 179,048 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 373,577 shares. The stock had previously closed at $9.82.

Wall Street Analyst Weigh In

INDV has been the topic of a number of analyst reports. Piper Sandler restated an “overweight” rating and issued a $22.00 price target on shares of Indivior in a research note on Friday, September 13th. Craig Hallum decreased their target price on shares of Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th.

Indivior Stock Performance

The stock’s fifty day simple moving average is $11.31 and its 200-day simple moving average is $14.88. The company has a market capitalization of $1.30 billion, a PE ratio of 944.00 and a beta of 0.68. The company has a quick ratio of 0.68, a current ratio of 0.85 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.04. The firm had revenue of $299.00 million during the quarter, compared to analysts’ expectations of $285.90 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. On average, research analysts predict that Indivior PLC will post 1.7 earnings per share for the current fiscal year.

Institutional Trading of Indivior

Institutional investors and hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC boosted its stake in shares of Indivior by 32.0% during the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock valued at $407,000 after acquiring an additional 6,121 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Indivior during the 2nd quarter worth about $188,000. VELA Investment Management LLC purchased a new stake in shares of Indivior during the second quarter worth about $235,000. XTX Topco Ltd acquired a new position in shares of Indivior in the second quarter valued at approximately $249,000. Finally, Chilton Investment Co. Inc. acquired a new position in shares of Indivior in the fourth quarter valued at approximately $263,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.